Regeneron Pharmaceuticals, Inc.
REGN
|
$894.35
0.04%
140K
|
Health Technology
(0.0% 1d) (-6.8% 1m) (12.9% 1y) (0.0% 2d) (0.0% 3d) (-1.5% 7d) (-23.89% volume)
Earnings Calendar: 2024-02-02
Market Cap: $ 96,539,492,813
http://www.regeneron.com
Sec Filling | Patents | 8100 employees
(United States) Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
scooters antibody optical genetic brands rice
Drugs
Arcalyst (rilonacept)Evkeeza (evinacumab)
EYLEA (aflibercept)
Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn)
LIBTAYO (cemiplimab-rwlc)
Praluent (alirocumab)
REGEN-COV (casirivimab and imdevimab)
add to watch list Paper trade email alert is off
Press-releases
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: 1.09%
H: 0.86%
C: -0.3%
KNSA | $16.76 -0.71% 70K
|
Health Technology
|
| O: 0.46%
H: 0.17%
C: -3.36%
first report pharmaceuticals financial results
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
NVS | $93.815 1.35% 410K
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: -1.94%
H: 0.43%
C: -0.34%
OCUL | News | $5.07 -13.48% 2.6M
|
Health Technology
|
| O: -1.03%
H: 3.66%
C: 1.7%
ocular key leaders
Opthea Appoints John Han, PharmD, as VP Medical Affairs
Published: 2024-04-08 (Crawled : 23:00) - globenewswire.com
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: 0.31%
H: 0.83%
C: 0.27%
OPT | $3.4 1.8K
|
Health Technology
|
| O: -2.73%
H: 3.57%
C: 3.32%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.37%
H: 0.38%
C: 0.06%
ADVM | $11.025 -1.12% 8.4K
|
Health Technology
|
| O: -0.4%
H: 1.52%
C: -4.15%
medical
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: 0.11%
H: 0.32%
C: -0.07%
response
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
Published: 2024-04-01 (Crawled : 20:00) - globenewswire.com
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: -0.7%
first conference report financial results
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Published: 2024-03-27 (Crawled : 23:00) - biospace.com/
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: 0.78%
H: 0.4%
C: -0.49%
ren026 fda study
Regeneron Provides Update on Biologics License Application for Odronextamab
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: -1.37%
H: 1.15%
C: 0.74%
license update application
Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.255 0.72% 200K
|
Health Technology
|
| O: 0.21%
H: 0.97%
C: 0.7%
NVS | $93.815 1.35% 410K
|
Health Technology
|
| O: 0.05%
H: 0.14%
C: -0.93%
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
LLY | $731.1 -1.99% 1M
|
Health Technology
|
| O: -0.7%
H: 0.73%
C: -0.16%
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: -0.27%
H: 1.26%
C: 0.84%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.2%
H: 1.14%
C: -1.18%
antibody therapeutics market
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
Published: 2024-03-13 (Crawled : 02:00) - globenewswire.com
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: -1.46%
million cancer research
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: 0.23%
H: 0.9%
C: -0.68%
praluent fda children genetic cholesterol approval treat injection
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Last 48 Hours Insiders Buying
CLSD | $1.42 7.58% 100K
|
Health Technology
|
14:00
CDZI P 25000 | $2.275 1.11% 74K
|
Utilities
|
14:00
ETST P 39000 | $0.068 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.47 1.4% 6.6K
|
Finance
|
12:30
ADMQ | $0.0532 480K
|
|
10:30
AXR P 2400 | $22.26 0.41% 180
|
Finance
|
21:00
QCRH P 118 | $56.105 1.25% 11K
|
Finance
|
18:01
VUZI P 7500 | $1.245 -1.19% 140K
|
Electronic Technology
|
18:00
RMCF | $3.5501 390
|
Consumer Non-Durables
|
20:10